Peter Gold

“As complex as it might seem, the market is merely a case of “people acting like people” — with all their fears, enthusiasms, prejudices, stupidity and wisdom. Together, we create prices. We are the market.” In this exclusive extract from his latest book Lessons From The Trader Wizard Bill Cara, the Trader Wizard and Free […]

A key question  for Apple (NASDAQ:AAPL) shareholders relates to its extremely high earnings per share (currently $41.02).  Investors have been able to ignore this warning sign because the company has maintained the popularity of its products, whilst generating new revenue streams and product lines.  The question is: how long will Apple sustain its earning levels? […]

On 1st July 2012, Facebook executives agreed to continue listing its stock on the NASDAQ exchange, despite struggling significantly since its IPO. In the first six weeks of public trading, Facebook’s share price (NASDAQ: FB) has dropped 19.02% with the company privately blaming NASDAQ for technical errors on the day of the IPO, as well […]

Google’s relatively high earnings per share ratio ($32.99) will interest many investors, with their beta rating (1.08), which measures a stock’s volatility relative to the market, is only slightly above the market average (1.00). These significant indicators identify Google of being in financial strength within the market. However, with the on-going investigations which could lead […]

Shares of Supergroup (LSE:SGP), parent of clothing retailer Superdry, lost roughly a third of their value on Friday after the company issued its second profit warning since February. This profit warning downgraded the company’s pre-tax profit for the year to April 29 to £43 million, after the warning in February had downgraded that figure to […]

GlaxoSmithKline (LSE:GSK), the pharmaceutical giant, announced today that it has launched an attempt to acquire Human Genome Services, a longtime research partner of the firm. GSK has offered to pay $13 a share for all of HGS’s outstanding shares, an 81% premium. HGS, which is currently valued at $7.17 a share, does not believe GSK’s […]

NBNK Investments (LSE:NBNK), an investment vehicle focused on domestic banking, appears to have become the leading bidder for 632 Lloyds Banking Group branches.  Lloyds is attempting to sell the branches as a condition of being bailed out by the government in 2008. NBNK is reportedly willing to bid between £1.5 million and £2 million according […]

Stellar Diamond (LSE:STEL), a West-African focused diamond mining and exploration company, announced today that its licences in the Kono region of Sierra Leone may well be in jeopardy. The Licences, initially granted in January of 2005, allow the company to carry out its operations in the region. The licences were renwed in May of last […]

Matra Petroleum (LSE:MTA), an independent oil exploration and production company with major operations in Russia, announced today that it has entered an agreement with Mr. Maxim Barskiy. Barskiy has agreed to buy 575 million new shares at a price of 0.8p per share, totalling £4.6 million. Pending shareholder approval, Mr. Barskiy will obtain a 29.8% […]

SkyePharma (LSE:SKP), a pharmaceutical company specialising in the development of inhaled products and drug delivery technologies, announced today that it has signed a second agreement to conduct a feasibility study with RespiVert, a small molecule drug discovery company specializing in respiratory disorders.   This agreement comes on the heels of the successful completion of a similar […]